| pubmed-article:8102515 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0001527 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0023796 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0016157 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0027996 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:8102515 | lifeskim:mentions | umls-concept:C0050558 | lld:lifeskim |
| pubmed-article:8102515 | pubmed:dateCreated | 1993-9-16 | lld:pubmed |
| pubmed-article:8102515 | pubmed:abstractText | To assess the possible benefits of combined hypolipidemic therapy (acipimox+marine fish oil) on lipid and lipoprotein metabolism, male Wistar rats were fed for 14 days a high sucrose diet (70 cal% sucrose) alone or a high sucrose diet supplemented with acipimox (0.2 g/100 g diet) and/or fish oil (1 ml orally daily; 30 wt% of n-3 PUFA). Feeding a high sucrose diet increased (control: 61 +/- 6 vs HS: 110 +/- 8 nmol.min-1.mg-1, p < 0.001) the activity of acetyl CoA carboxylase in the liver, this was normalized by fish oil but not acipimox alone (HS+FO: 68 +/- 4; HS+ACI: 95 +/- 4; HS+ACI+FO: 71 +/- 2 nmol.min-1.mg-1). Increased triglyceride concentration in serum and muscle tissue (m. soleus and heart) of high sucrose-fed animals was suppressed equally by fish oil, acipimox, and/or both. The cholesterol-lowering effect of fish oil was also present in the liver (p < 0.005). The cholesterol-lowering action of acipimox was accompanied by the accumulation of cholesterol in the liver (p < 0.005), whereas the combination of acipimox+fish oil did not change the liver cholesterol content. After fish oil the LDL binding capacity of liver plasma membranes was increased 1.6-fold (p < 0.001). LDL receptor activity was significantly decreased in HS+ACI group (p < 0.05), but remained unchanged in HS+FO+ACI-fed animals. In summary, (a) the hypotriglyceridemic effect of fish oil in high sucrose-induced HTG is due to its inhibitory effects at the level of fatty acid synthesis; (b) decreased triglyceride production and output from the liver prevent triglyceride accumulation in muscle tissue; (c) the cholesterol-lowering action of acipimox but not fish oil was accompanied by an accumulation of cholesterol in the liver; (d) the latter phenomenon may be due to the opposite effects of both drugs on cholesterol catabolism via hepatic LDL receptors. | lld:pubmed |
| pubmed-article:8102515 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8102515 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8102515 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8102515 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8102515 | pubmed:issn | 0077-8923 | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:HermannMM | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:KlimesII | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:HromadováMM | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:SebökováEE | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:MitkováAA | lld:pubmed |
| pubmed-article:8102515 | pubmed:author | pubmed-author:MinchenkoAA | lld:pubmed |
| pubmed-article:8102515 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8102515 | pubmed:day | 14 | lld:pubmed |
| pubmed-article:8102515 | pubmed:volume | 683 | lld:pubmed |
| pubmed-article:8102515 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8102515 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8102515 | pubmed:pagination | 183-91 | lld:pubmed |
| pubmed-article:8102515 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:meshHeading | pubmed-meshheading:8102515-... | lld:pubmed |
| pubmed-article:8102515 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8102515 | pubmed:articleTitle | Modulation of the hypolipidemic effect of fish oil by inhibition of adipose tissue lipolysis with acipimox, a nicotinic acid analog. | lld:pubmed |
| pubmed-article:8102515 | pubmed:affiliation | Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava. | lld:pubmed |
| pubmed-article:8102515 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8102515 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
